Short-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis
Authors:
Open Access
- 13 January 2025
- journal article
- research article
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-8
Abstract
To explore the effect of short-acting growth hormone (GH) supplementation on bone age and growth rate of children with idiopathic short stature. The authoritative databases such as PubMed, Medline, and Web of Science were extensively searched through the systematic and comprehensive literature retrieval strategy to compile the clinical research data on the treatment of idiopathic short stature with short-acting GH. The study will be strictly screened to ensure that all enrolled research subjects are patients with idiopathic short stature, and the intervention method is defined as short-acting GH replacement therapy, and a reasonable control group is set, such as placebo treatment, to ensure the scientificity and comparability of research results. Outcome index data such as basic characteristics, sample size, follow-up time, and total effective rate of the included studies were extracted. In this study, RevMan 5.3, a professional statistical software tool, was used to systematically perform the meta-analysis process. Weighted average difference (WMD) was calculated as the primary outcome to evaluate the effect of bone age and growth rate, and the WAD in adverse reactions was considered as the secondary outcome. Nine studies were included in the study, and 491 patients with idiopathic short stature were included in the study. The results of the meta-analysis showed that there was no significant difference in bone age but a significant difference in growth rate when compared with the control group. Short-acting GH supplementation can significantly improve the growth rate of children with idiopathic short stature, but has little effect on bone age.Keywords
This publication has 30 references indexed in Scilit:
- Regulation of GH and GH Signaling by NutrientsCells, 2021
- Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunctionThe Lancet Diabetes & Endocrinology, 2021
- Responses to growth hormone (GH) therapy in short children with normal GH secretion and no bone age delay: an analysis of potential factors affecting their response to rhGH therapy. A controlled study.2019
- Effect of Growth Hormone Treatment on Adult Height in Peripubertal Children with Idiopathic Short Stature: A Randomized, Double-Blind, Placebo-Controlled TrialThe Journal of Clinical Endocrinology & Metabolism, 2004
- High dose growth hormone treatment induces acceleration of skeletal maturation and an earlier onset of puberty in children with idiopathic short statureArchives of Disease in Childhood, 2002
- Final Height Gain by GH Therapy in Children with Idiopathic Short Stature Is Dose DependentThe Journal of Clinical Endocrinology & Metabolism, 2002
- Randomised trial of growth hormone in short normal girlsThe Lancet, 1998
- Growth parameters and predictors of growth in short children with and without growth hormone (GH) deficiency treated with human GH: a randomized controlled studyJournal of Tropical Pediatrics, 1996
- Combined treatment with growth hormone and luteinizing hormone releasing hormone-analogue (LHRHa) of pubertal children with familial short statureJournal of Endocrinological Investigation, 1993
- Effects of Growth Hormone in Short, Slowly Growing Children without Growth Hormone DeficiencyActa Paediatrica, 1990